House Bill 1121 in the Colorado Legislature is being sold as a way to bring down the price of a certain classification of drugs called "biosimilars;" it's not.
HB 1121 is an attempt to pre-empt the U.S. Food and Drug Administration (FDA) on biosimilar products. We should be more concerned about protecting the public health by ensuring the safety, efficacy and security of human and veterinary drugs, biological products and medical products by the FDA before they go to market.
HB 1121 is a complicated and confusing bill by design. It is being promoted by two drug companies that want to impede the ability of the market to develop less expensive options of some important medications.
The big question is why Colorado would want to get involved in an issue when the FDA is still considering its options. We have a process that must be followed. Why would we legislate something that doesn?t even exist yet?
Jack Beckner, Dillon